-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) opened more than 3%, partner Spruce has split the CRHX-101 project into AdrenyX
Share
Listen to the news

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) opened more than 3% higher. As of press release, it rose 3.27% to HK$10.43, with a turnover of HK$199,200.

According to the news, on November 18, Platinum Pharmaceutical-B announced that the company's partner Spruce Biosciences Inc. (NASDAQ: SPRB) (Spruce) has split its CRHX-101 (also known as HBM9013/ HAT001/SPR-202) project into Adrenyx Biosciences, Inc. (Adrenyx), a newly established wholly-owned subsidiary of Spruce, and Adrenyx is expected to be in 2027 Listed on NASDAQ in the first half of the year. Upon completion of the plan to distribute Adrenyx common shares in proportion to Spruce shareholders, and Platinum Pharmaceuticals are expected to hold shares in Spruce and Adrenyx at the same time.

CRHX-101 is a monoclonal antibody designed and developed to treat congenital adrenal hyperplasia. Adrenyx plans to submit a new drug clinical trial application for CRHX-101 to the US Food and Drug Administration, and then begin clinical development. CRHX-101 is derived from HBM Alpha Therapeutics (HBMAT), a subsidiary of which the Company holds a majority interest. In January 2025, HBMAT signed a cooperation and licensing agreement with Spruce, granting Spruce the exclusive global right to develop and commercialize CRHX-101 outside of Greater China (Mainland China, Taiwan, Hong Kong, and Macau, China).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending